Feb 13, 2013, 09.13 AM | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Lupin.
Sudarshan Sukhani (more)
Technical Analyst, s2analytics.com | Capital Expertise: Equity - Technical
Sukhani told CNBC-TV18, " Lupin has been fairly choppy but in that choppiness there is an underlying uptrend. We had a very sharp correction and that correction seems to be over now. Yesterday price action was very decent, that tells us that Lupin is likely to go and test its earlier highs. So Lupin is a buying opportunity."
He further added, "Again these are one-two day trades, there is no need to get married to the stocks but it is worthwhile. If we have a sudden sharp rally in the Nifty a lot of these things will work out."
The share touched its 52-week high Rs 631.90 and 52-week low Rs 483.50 on 10 September, 2012 and 22 February, 2012, respectively. Currently, it is trading 4.24% below its 52-week high and 25.15% above its 52-week low. Market capitalisation stands at Rs 27,076.13 crore.
The company's US-based subsidiary Gavis Pharmaceut
Lupin's US subsidiary, Gavis Pharmaceuticals LLC.,
Avinash Gorakshakar, Market Expert is of the view
Prakash Gaba of prakashgaba.com is of the view tha
"Acotiamide is a first-in-class novel drug to be i